Search research articles
Contact Us
Filters
Showing results (21-30 of 299) with videos related to
Page
of 30
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel
Samuel Martel, Matteo Lambertini, Evandro de Azambuja
Ecancermedicalscience
|
December 1, 2016
Phosphoethanolamine and the danger of unproven drugs
Noam Pondé, Evandro de Azambuja, Felipe Ades
ESMO Open
|
November 18, 2020
CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
Elisa Agostinetto, Rafael Caparica, Evandro de Azambuja
ESMO Open
|
August 2, 2017
Male breast cancer: finding the way in this uncommon path
Christian Maurer, Samuel Martel, Evandro de Azambuja
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2020
Are We RESPECTing Older Patients With Breast Cancer?
Evandro de Azambuja, Noam Pondé, Richard D Gelber
European Journal of Cancer (Oxford, England : 1990)
|
January 8, 2008
Current perspectives of epothilones in breast cancer
Fatima Cardoso, Evandro de Azambuja, Lissandra Dal Lago
Cancer Treatment Reviews
|
March 15, 2023
Optimizing treatment for HER2-positive HR-positive breast cancer
Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Future Oncology (London, England)
|
April 3, 2019
Pertuzumab in HER2-positive early breast cancer: current use and perspectives
Daniel Eiger, Noam Falbel Pondé, Evandro de Azambuja
ESMO Open
|
November 16, 2016
Twenty years of anti-HER2 therapy-associated cardiotoxicity
Noam F Pondé, Matteo Lambertini, Evandro de Azambuja
Current Cancer Drug Targets
|
March 12, 2009
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer
Philippe L Bedard, Evandro de Azambuja, Fatima Cardoso
Page
of 30
Search research articles
Search
Showing results (21-30 of 299) with videos related to
Sort By:
Page
of 30
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2022
Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel
Samuel Martel, Matteo Lambertini, Evandro de Azambuja
Ecancermedicalscience
|
December 1, 2016
Phosphoethanolamine and the danger of unproven drugs
Noam Pondé, Evandro de Azambuja, Felipe Ades
ESMO Open
|
November 18, 2020
CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
Elisa Agostinetto, Rafael Caparica, Evandro de Azambuja
ESMO Open
|
August 2, 2017
Male breast cancer: finding the way in this uncommon path
Christian Maurer, Samuel Martel, Evandro de Azambuja
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2020
Are We RESPECTing Older Patients With Breast Cancer?
Evandro de Azambuja, Noam Pondé, Richard D Gelber
European Journal of Cancer (Oxford, England : 1990)
|
January 8, 2008
Current perspectives of epothilones in breast cancer
Fatima Cardoso, Evandro de Azambuja, Lissandra Dal Lago
Cancer Treatment Reviews
|
March 15, 2023
Optimizing treatment for HER2-positive HR-positive breast cancer
Veronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Future Oncology (London, England)
|
April 3, 2019
Pertuzumab in HER2-positive early breast cancer: current use and perspectives
Daniel Eiger, Noam Falbel Pondé, Evandro de Azambuja
ESMO Open
|
November 16, 2016
Twenty years of anti-HER2 therapy-associated cardiotoxicity
Noam F Pondé, Matteo Lambertini, Evandro de Azambuja
Current Cancer Drug Targets
|
March 12, 2009
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer
Philippe L Bedard, Evandro de Azambuja, Fatima Cardoso
Page
of 30